This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Biotech Stock Mailbag: Dendreon's Aftermath

Stocks in this article: DNDNSPPIPATHVRTXSGENALTHAMAG

If Spectrum had real visibility into Fusilev's performance, especially vs. cheaper, generic leucovorin, it would give sales guidance. The company still chooses not to do so.

Zevalin sales totaled $8.4 million in the June quarter, up 42% sequentially. That's a nice turnaround, but I would also mention that Zevalin sales are now only just back to fourth-quarter levels. Spectrum continues to forecast "modest" Zevalin growth.

I'm a stubborn Spectrum bear and I see no reason yet to change my stance, particularly around the Fusilev vs. leucovorin issues. The main risk to the bear thesis is if Spectrum is successful in signing up enough physician practices to long-term Fusilev supply agreements to ensure the drug's continued growth even if or when generic leucovorin supplies are more fully replenished.

Spectrum mentioned these customer agreements on the call, so it's definitely worth noting if you're short the stock, and it's a reason to be optimistic if you're long.

One buy-side source whom I respect recently took a long position in Spectrum based on his belief that Fusilev sales will grow even with increased competition from cheaper leucovorin. I'll let him explain:

"We believe this business Fusilev will last and grow from accounts we have spoken to. Economic reasons play a part and also dosing error phenomenon is now playing a role in why doctors are fed up with switching back and forth from generic leucovorin… This is something doctors are telling us is a sticky issue in their practice," this buy-side investor tells me. He's long Spectrum but is not allowed to speak on the record to the media.


One drop-dead rule for biotech investing (any investing, actually) is to read closely a company's regulatory filings. What a company discloses to the Securities and Exchange Commission in an 8-K, 10-Q or 10-K is much more important than what's trumpeted in a press release.

Don't ignore press releases. Instead, compare the language and details scripted in the press release to what's disclosed in the SEC filings. If the two documents differ, i.e., if the press release leaves out salient yet less-than-positive details, you can infer that management may be more interested in spin than transparency.

3 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs